Donald Hooker
Stock Analyst at Keybanc
(2.86)
# 1,533
Out of 4,814 analysts
82
Total ratings
55.95%
Success rate
17.03%
Average return
Main Sectors:
Stocks Rated by Donald Hooker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: Overweight | $180 → $100 | $6.83 | +1,364.13% | 18 | Feb 23, 2022 | |
| CRL Charles River Laboratories International | Maintains: Overweight | $450 → $390 | $105.93 | +268.17% | 5 | Feb 17, 2022 | |
| DGX Quest Diagnostics | Maintains: Overweight | $168 → $170 | $163.77 | +3.80% | 4 | Dec 13, 2021 | |
| IQV IQVIA Holdings | Maintains: Overweight | $270 → $290 | $143.91 | +101.51% | 4 | Nov 17, 2021 | |
| PHR Phreesia | Maintains: Overweight | $70 → $73 | $23.94 | +204.93% | 8 | Jul 12, 2021 | |
| RXRX Recursion Pharmaceuticals | Initiates: Overweight | $36 | $5.50 | +554.55% | 1 | May 11, 2021 | |
| AMWL American Well | Initiates: Sector Weight | n/a | $6.99 | - | 1 | Apr 16, 2021 | |
| VEEV Veeva Systems | Maintains: Overweight | $332 → $353 | $220.66 | +59.97% | 2 | Feb 17, 2021 | |
| HQY HealthEquity | Downgrades: Sector Weight | n/a | $84.52 | - | 11 | Dec 2, 2020 | |
| MMS Maximus | Maintains: Overweight | $80 → $84 | $67.23 | +24.94% | 2 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $8.97 | - | 8 | Jul 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $170 | $217.06 | -21.68% | 7 | Mar 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $139.30 | - | 6 | Sep 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $68 → $46 | $1.35 | +3,307.41% | 2 | Nov 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $19.45 | - | 1 | Oct 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $296.28 | - | 2 | Jul 10, 2017 |
Teladoc Health
Feb 23, 2022
Maintains: Overweight
Price Target: $180 → $100
Current: $6.83
Upside: +1,364.13%
Charles River Laboratories International
Feb 17, 2022
Maintains: Overweight
Price Target: $450 → $390
Current: $105.93
Upside: +268.17%
Quest Diagnostics
Dec 13, 2021
Maintains: Overweight
Price Target: $168 → $170
Current: $163.77
Upside: +3.80%
IQVIA Holdings
Nov 17, 2021
Maintains: Overweight
Price Target: $270 → $290
Current: $143.91
Upside: +101.51%
Phreesia
Jul 12, 2021
Maintains: Overweight
Price Target: $70 → $73
Current: $23.94
Upside: +204.93%
Recursion Pharmaceuticals
May 11, 2021
Initiates: Overweight
Price Target: $36
Current: $5.50
Upside: +554.55%
American Well
Apr 16, 2021
Initiates: Sector Weight
Price Target: n/a
Current: $6.99
Upside: -
Veeva Systems
Feb 17, 2021
Maintains: Overweight
Price Target: $332 → $353
Current: $220.66
Upside: +59.97%
HealthEquity
Dec 2, 2020
Downgrades: Sector Weight
Price Target: n/a
Current: $84.52
Upside: -
Maximus
Aug 7, 2020
Maintains: Overweight
Price Target: $80 → $84
Current: $67.23
Upside: +24.94%
Jul 6, 2020
Downgrades: Sector Weight
Price Target: n/a
Current: $8.97
Upside: -
Mar 30, 2020
Maintains: Overweight
Price Target: $212 → $170
Current: $217.06
Upside: -21.68%
Sep 23, 2019
Downgrades: Sector Weight
Price Target: n/a
Current: $139.30
Upside: -
Nov 13, 2017
Maintains: Overweight
Price Target: $68 → $46
Current: $1.35
Upside: +3,307.41%
Oct 24, 2017
Downgrades: Sector Weight
Price Target: n/a
Current: $19.45
Upside: -
Jul 10, 2017
Downgrades: Sector Weight
Price Target: n/a
Current: $296.28
Upside: -